For decades, the idea of a drug that could rewind aspects of human aging has belonged more to science fiction than hospital formularies. That boundary is starting to blur as a gene therapy called ...

Aging is the primary risk factor for numerous life-threatening diseases and has long been a central focus of biological research. Epigenetic reprogramming, a process that can modulate cell fate and ...

BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, ...

Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...

nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA-1001 for the Treatment of Chronic Hepatitis B First CTA authorization ...

Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing first-in-human, open-label study evaluating EPI-321, an investigational ...

(Paris, France, Tuesday, 1 July 2025) Novel research presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) has found that embryos from women ...